Sepsis Diagnostics Market by Technology (Microbiology, PCR, Microarray, Immunoassay, Biomarkers), Product (Reagents, Assay, Instruments, Software), Method, Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End User and Region - Global Forecast to 2025

敗血症診断の世界市場予測:技術別(微生物学、PCR、マイクロアレイ、イムノアッセイ、バイオマーカー)、製品別(試薬、アッセイ、機器、ソフトウェア)、方法別、テスト種類別(ラボ、POC)、病原体別(細菌、真菌)、エンドユーザー別、地域別

◆タイトル:Sepsis Diagnostics Market by Technology (Microbiology, PCR, Microarray, Immunoassay, Biomarkers), Product (Reagents, Assay, Instruments, Software), Method, Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End User and Region - Global Forecast to 2025
◆商品コード:MD 4575
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年5月20日
◆ページ数:200
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥519,750見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥698,250見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥855,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社は敗血症診断の世界市場が2019年4億2900万ドルから2025年7億ドルまで、年平均8.5%成長すると予測しています。本調査レポートでは、敗血症診断の世界市場を詳細に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、技術別(血液培養、イムノアッセイ、分子診断、フローサイトメトリー、マイクロ流体、バイオマーカー)、製品別(血液培養培地、アッセイ&試薬、計器、ソフトウェア)、方法別(従来型診断、自動型診療)、病原体別(細菌性敗血症、真菌性敗血症、その他)、テストタイプ別(実験室試験、ケアポイントテスト)、エンドユーザー別(病院、物理&参照研究所、研究室&学術機関)、地域別、競争状況、企業概要などを含め、ご提供いたします。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・敗血症診断の世界市場:技術別(血液培養、イムノアッセイ、分子診断、フローサイトメトリー、マイクロ流体、バイオマーカー)
・敗血症診断の世界市場:製品別(血液培養培地、アッセイ&試薬、計器、ソフトウェア)
・敗血症診断の世界市場:方法別(従来型診断、自動型診療)
・敗血症診断の世界市場:病原体別(細菌性敗血症、真菌性敗血症、その他)
・敗血症診断の世界市場:テストタイプ別(実験室試験、ケアポイントテスト)
・敗血症診断の世界市場:エンドユーザー別(病院、物理&参照研究所、研究室&学術機関)
・敗血症診断の世界市場:地域別
・競争状況
・企業概要

“The global sepsis diagnostics market is projected to grow at a CAGR of 8.5% during the forecast period.”
The global sepsis diagnostics market size is expected to reach USD 700 million by 2025 from USD 429 million in 2019, at a CAGR of 8.5%. The demand is expected to grow due to the rising incidence of sepsis, a growing number of surgical procedures, high incidence of hospital-acquired infections, and increasing availability of a wide variety of sepsis diagnostic devices. The sepsis diagnostics industry is segmented on the technology, product, method, pathogen, test type, end user, and region.

“The blood culture segment accounted for the largest share of the sepsis diagnostics industry, by end-user, in 2019.”
Based on end-users, the sepsis diagnostics market is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. In 2019, blood culture accounted for the largest share of the market due to the increasing incidences of sepsis coupled with the growing adoption of blood culture techniques for the diagnosis of sepsis.

“The blood culture media segment accounted for the largest share of the sepsis diagnostics market, by product, in 2019.”
The market, by product, is segmented into blood culture media, assays & reagents, instruments, and software. In 2019, the blood culture media segment accounted for the largest share of the sepsis diagnostics industry due to the usage of blood culture testing as the standard diagnostic method for the diagnosis and identification of sepsis across the globe.

“North America accounted for the largest share of the sepsis diagnostics market in 2019.”
North America accounted for the largest share of the global market in 2019, followed by Europe. This can primarily be attributed to the extensive availability of advanced sepsis diagnostic technologies, well-established distribution channels, and significant public awareness about the clinical benefits of diagnostic products in risk assessment for infectious diseases.

Breakdown of supply-side primary interviews:
• By Company Type: Tier 1 (48%), Tier 2 (36%), and Tier 3 (16%)
• By Designation: C-level (10%), Director-level (14%), and Others (76%)
• By Region: North America (40%), Europe (32%), APAC (20%), and RoW (8%)

Some of the prominent players in the sepsis diagnostics market are bioMérieux (France), Becton Dickinson Company (US), Danaher (US), Abbott Laboratories (US), Roche Diagnostics (Switzerland), T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), and CytoSorbents (US).
Research Coverage
This report studies the sepsis diagnostics market based on technology, product, method, pathogen, test type, end-user, and region. It studies significant factors (such as drivers and restraints) affecting the market growth. The report also analyzes opportunities and challenges in the market for stakeholders. It provides details of the competitive landscape for market leaders with respect to their growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views. It also analyzes the competitive landscape users emerging segments of the sepsis diagnostics market; and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 19)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. – 22)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 PROCEDURE-BASED MARKET ESTIMATION
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. – 31)

4 PREMIUM INSIGHTS (Page No. – 36)
4.1 SEPSIS DIAGNOSTICS: MARKET OVERVIEW
4.2 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY
4.3 GEOGRAPHIC ANALYSIS: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT AND REGION
4.4 APAC: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY AND END USER
4.5 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN
4.6 GEOGRAPHIC SNAPSHOT OF THE SEPSIS DIAGNOSTICS MARKET

5 MARKET OVERVIEW (Page No. – 40)
5.1 INTRODUCTION
5.2 MARKET DINAMICS
5.2.1 DRIVERS
5.2.1.1 High incidence of sepsis
5.2.1.2 Rising incidence of hospital-acquired infections
5.2.1.3 Growing funding for sepsis-related research
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario
5.2.2.2 High cost of automated diagnostic devices
5.2.3 OPPORTUNITIES
5.2.3.1 Development of rapid diagnostic/POC techniques for early sepsis diagnosis
5.2.3.2 Evolution of novel biomarkers for sepsis diagnosis
5.2.4 CHALLENGES
5.2.4.1 Lack of standard protocols and awareness
5.2.4.2 Shortage of skilled healthcare professionals

6 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. – 46)
6.1 INTRODUCTION
6.2 BLOOD CULTURE
6.2.1 BLOOD CULTURE HOLDS THE LARGEST SHARE OF THE TECHNOLOGY MARKET
6.3 IMMUNOASSAYS
6.3.1 PRODUCT DEVELOPMENT EFFORTS BY MAJOR PLAYERS HAVE ENSURED DEMAND FOR IMMUNOASSAYS
6.4 MOLECULAR DIAGNOSTICS
6.4.1 POLYMERASE CHAIN REACTION
6.4.1.1 PCR holds the largest share of the molecular diagnostics market
6.4.2 MICROARRAYS
6.4.2.1 Simultaneous analysis capabilities, accuracy, and rapidity have driven the use of microarrays
6.4.3 PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION
6.4.3.1 PNA-FISH kits allow for the rapid diagnosis of BSIs
6.4.4 SYNDROMIC PANEL-BASED TESTING
6.4.4.1 High costs and accuracy issues have affected test adoption
6.5 FLOW CYTOMETRY
6.5.1 LACK OF STANDARDIZED PROTOCOLS IS A KEY RESTRAINT IN THIS MARKET SEGMENT
6.6 MICROFLUIDICS
6.6.1 GROWING ADOPTION OF ADVANCED & RAPID TESTING WILL FAVOR MARKET GROWTH IN THIS SEGMENT
6.7 BIOMARKERS
6.7.1 DESPITE POTENTIAL, NO SINGLE IDEAL BIOMARKER HAS BEEN IDENTIFIED FOR SEPSIS DIAGNOSTICS

7 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT (Page No. – 71)
7.1 INTRODUCTION
7.2 BLOOD CULTURE MEDIA
7.2.1 BLOOD CULTURE MEDIA DOMINATE THE PRODUCTS MARKET
7.3 ASSAYS & REAGENTS
7.3.1 INCREASING AWARENESS HAS DRIVEN THE USE OF ASSAYS & REAGENTS
7.4 INSTRUMENTS
7.4.1 MARKET IS CHARACTERIZED BY A SHIFT FROM TRADITIONAL & MANUAL INSTRUMENTS TO AUTOMATED SYSTEMS
7.5 SOFTWARE
7.5.1 RISING USE OF AUTOMATED INSTRUMENTS WILL ENSURE DEMAND FOR SOFTWARE

8 SEPSIS DIAGNOSTICS MARKET, BY METHOD (Page No. – 76)
8.1 INTRODUCTION
8.2 CONVENTIONAL DIAGNOSTICS
8.2.1 CONVENTIONAL DIAGNOSTICS HOLDS LARGEST MARKET SHARE
8.3 AUTOMATED DIAGNOSTICS
8.3.1 AUTOMATED DIAGNOSTICS SEGMENT TO GROW AT THE HIGHEST CAGR

9 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN (Page No. – 80)
9.1 INTRODUCTION
9.2 BACTERIAL SEPSIS
9.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS
9.2.1.1 Gram-negative bacteria cause ~50% of sepsis infections
9.2.2 GRAM-POSITIVE BACTERIAL SEPSIS
9.2.2.1 Cases of sepsis caused by gram-positive bacteria have risen in recent years
9.3 FUNGAL SEPSIS
9.3.1 FUNGEMIA IS THE SECOND-BIGGEST CAUSE OF BLOODSTREAM INFECTIONS
9.4 OTHER PATHOGENS

10 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE (Page No. – 86)
10.1 INTRODUCTION
10.2 LABORATORY TESTS
10.2.1 LABORATORY TESTS ARE THE MOST COMMON AND PREFERRED MODE OF TESTING
10.3 POINT-OF-CARE TESTS
10.3.1 RAPIDITY AND CONVENIENCE HAVE DRIVEN DEMAND FOR POC TESTS

11 SEPSIS DIAGNOSTICS MARKET, BY END USER (Page No. – 90)
11.1 INTRODUCTION
11.2 HOSPITALS
11.2.1 HOSPITALS HOLD THE LARGEST SHARE OF THE SEPSIS DIAGNOSTICS MARKET
11.3 PATHOLOGY & REFERENCE LABORATORIES
11.3.1 INDEPENDENT LABORATORIES OFFER AFFORDABILITY AS WELL AS THE BENEFITS OF BUNDLED SERVICES
11.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
11.4.1 GOVERNMENT SUPPORT AND RISING AWARENESS HAVE ENSURED DEMAND FOR MARKET PRODUCTS IN THIS SEGMENT

12 SEPSIS DIAGNOSTICS MARKET, BY REGION (Page No. – 94)
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 US
12.2.1.1 US is the largest market for sepsis diagnostics
12.2.2 CANADA
12.2.2.1 Growing availability of sepsis diagnostic products to support market growth in Canada
12.3 EUROPE
12.3.1 GERMANY
12.3.1.1 Germany accounted for the largest share of the European market
12.3.2 FRANCE
12.3.2.1 High incidence and rising awareness have supported the demand for sepsis diagnostics in France
12.3.3 UK
12.3.3.1 Government support and rising awareness are key drivers in the UK
12.3.4 ITALY
12.3.4.1 Sluggish growth in the Italian healthcare sector in the last few years to restrain the market growth
12.3.5 SPAIN
12.3.5.1 Rising sepsis incidence to drive market growth in Spain
12.3.6 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 JAPAN
12.4.1.1 Significant growth in pneumonia and infectious disease incidence to support market growth in Japan
12.4.2 CHINA
12.4.2.1 Healthcare infrastructure improvements to support market growth in China
12.4.3 INDIA
12.4.3.1 Increasing patient population and rising number of surgical procedures are key growth drivers in India
12.4.4 AUSTRALIA
12.4.4.1 Increasing number of sepsis treatment procedures indicates growth potential in the Australian market
12.4.5 SOUTH KOREA
12.4.5.1 Rising healthcare spending supports market growth in South Korea
12.4.6 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 BRAZIL
12.5.1.1 Brazil accounted for the largest share of the LATAM market
12.5.2 MEXICO
12.5.2.1 Rising medical tourism to support market growth in Mexico
12.5.3 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 HIGH CONSUMPTION OF IMMUNE SYSTEM-SUPPRESSING MEDICATIONS IS DRIVING SEPSIS OCCURRENCE

13 COMPETITIVE LANDSCAPE (Page No. – 135)
13.1 OVERVIEW
13.2 MARKET SHARE ANALYSIS
13.3 COMPETITIVE SCENARIO
13.3.1 PRODUCT LAUNCHES AND APPROVALS, 2016–2020
13.3.2 PARTNERSHIPS AND COLLABORATIONS, 2016–2020
13.3.3 MERGERS AND ACQUISITIONS, 2016–2020
13.3.4 MARKET EXPANSION, 2016–2020
13.4 COMPETITIVE LEADERSHIP MAPPING
13.4.1 VISIONARY LEADERS
13.4.2 INNOVATORS
13.4.3 DYNAMIC DIFFERENTIATORS
13.4.4 EMERGING COMPANIES

14 COMPANY PROFILES (Page No. – 141)
(Business Overview, Products Offered, Recent Developments, MnM View)*
14.1 BIOMÉRIEUX
14.2 BECTON, DICKINSON AND COMPANY
14.3 DANAHER
14.4 T2 BIOSYSTEMS
14.5 LUMINEX
14.6 ROCHE DIAGNOSTICS
14.7 THERMO FISHER SCIENTIFIC
14.8 BRUKER CORPORATION
14.9 ABBOTT
14.10 IMMUNEXPRESS
14.11 RESPONSE BIOMEDICAL
14.12 AXIS-SHIELD DIAGNOSTICS
14.13 CYTOSORBENTS
14.14 MITSUBISHI CHEMICAL EUROPE
14.15 EKF DIAGNOSTICS
14.16 EMERGING PLAYERS
14.16.1 SEEGENE
14.16.2 GENMARK DIAGNOSTICS
14.16.3 BODITECH MED
14.16.4 ALPHA LABORATORIES
14.16.5 ALIFAX S.R.L.
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.



★調査レポート[敗血症診断の世界市場予測:技術別(微生物学、PCR、マイクロアレイ、イムノアッセイ、バイオマーカー)、製品別(試薬、アッセイ、機器、ソフトウェア)、方法別、テスト種類別(ラボ、POC)、病原体別(細菌、真菌)、エンドユーザー別、地域別] ( Sepsis Diagnostics Market by Technology (Microbiology, PCR, Microarray, Immunoassay, Biomarkers), Product (Reagents, Assay, Instruments, Software), Method, Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End User and Region - Global Forecast to 2025 / MD 4575) 販売に関する免責事項
[敗血症診断の世界市場予測:技術別(微生物学、PCR、マイクロアレイ、イムノアッセイ、バイオマーカー)、製品別(試薬、アッセイ、機器、ソフトウェア)、方法別、テスト種類別(ラボ、POC)、病原体別(細菌、真菌)、エンドユーザー別、地域別] ( Sepsis Diagnostics Market by Technology (Microbiology, PCR, Microarray, Immunoassay, Biomarkers), Product (Reagents, Assay, Instruments, Software), Method, Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End User and Region - Global Forecast to 2025 / MD 4575) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆